Evidence map›Paper›PMID 38399238›Full record

ReviewPharmaceutics2024

Recent Trends in Curcumin-Containing Inorganic-Based Nanoparticles Intended for In Vivo Cancer Therapy.

Douglas Dourado, Júlio Abreu Miranda, Matheus Cardoso de Oliveira, Danielle Teixeira Freire, Francisco Humberto Xavier-Júnior, Edgar Julian Paredes-Gamero, Éverton do Nascimento Alencar

Abstract readReview
In one paragraph

Review in Pharmaceutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Douglas DouradoDepartment of Immunology, Aggeu Magalhães Institute (IAM), Oswaldo Cruz Foundation (FIOCRUZ), Recife 50670-420, PE, Brazil.ORCID 0000-0003-3445-5217
Júlio Abreu MirandaDepartment of Pharmacy, Federal University of Rio Grande do Norte (UFRN), Natal 59010-180, RN, Brazil.ORCID 0000-0003-0783-7447
Matheus Cardoso de OliveiraDepartment of Pharmacy, Federal University of Rio Grande do Norte (UFRN), Natal 59010-180, RN, Brazil.ORCID 0000-0003-2137-6157
Danielle Teixeira FreireCollege of Pharmaceutical Sciences, Food and Nutrition, Federal University of Mato Grosso do Sul (UFMS), Campo Grande 79070-900, MS, Brazil.ORCID 0000-0003-3480-1968
Francisco Humberto Xavier-JúniorLaboratory of Pharmaceutical Biotechnology (BioTecFarm), Department of Pharmacy, Federal University of Paraíba (UFPB), João Pessoa 58051-900, PB, Brazil.ORCID 0000-0001-8238-3380
Edgar Julian Paredes-GameroCollege of Pharmaceutical Sciences, Food and Nutrition, Federal University of Mato Grosso do Sul (UFMS), Campo Grande 79070-900, MS, Brazil.
Éverton do Nascimento AlencarCollege of Pharmaceutical Sciences, Food and Nutrition, Federal University of Mato Grosso do Sul (UFMS), Campo Grande 79070-900, MS, Brazil.ORCID 0000-0002-6148-6804

Funding

National Council for Scientific and Technological Development Scholarship
6 · The paper itself

Abstract

Curcumin is a natural compound that has been widely investigated thanks to its various biological properties, including antiproliferative. This molecule acts on different cancers such as lung, breast, pancreatic, colorectal, etc. However, the bioactive actions of curcumin have limitations when its physicochemical properties compromise its pharmacological potential. As a therapeutic strategy against cancer, curcumin has been associated with inorganic nanoparticles. These nanocarriers are capable of delivering curcumin and offering physicochemical properties that synergistically enhance anticancer properties. This review highlights the different types of curcumin-based inorganic nanoparticles and discusses their physicochemical properties and in vivo anticancer activity in different models of cancer.

Indexed as

curcuminoidsnanotechnologyoncologypre-clinical

Identifiers

PMID38399238
PMCPMC10891663

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.